IPCA LABORATORIES LTD. - 524494 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under regulation 39(3) of SEBI (LODR), Regulation, 2015 for Loss of share certificate25-01-2024
25-01-2024
IPCA LABORATORIES LTD. - 524494 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Duplicate Share Certificate22-01-2024
IPCA LABORATORIES LTD. - 524494 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results For The 3Rd Quarter And Nine Months Ended 31.12.2023
IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results for the 3rd quarter and nine months ended 31.12.202322-01-2024
IPCA LABORATORIES LTD. - 524494 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Share Certificate11-01-2024
IPCA LABORATORIES LTD. - 524494 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 202310-01-2024
IPCA LABORATORIES LTD. - 524494 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Certificate04-01-2024
F&O Strategy: Buy Ipca Laboratories futures
Since the December contracts are nearing expiry, traders can consider buying January futures23-12-2023
IPCA LABORATORIES LTD. - 524494 - Closure of Trading Window
Closure of Trading Window for Unaudited Financial Results for the 3rd quarter and nine months ended 31.12.202321-12-2023
IPCA LABORATORIES LTD. - 524494 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificates22-11-2023
This pharma company outperformed Indian pharma market growth in October. What's the road ahead?
Stock Market Today- Indian Pharma market (IPM) growth picked up pace in October 2023 at 16.5% YoY led by rebound in the Acute segment growth and low base of the previous year. IPCA Labs with growth at 24% in October outperformed the IPM growth.16-11-2023